Gyre Therapeutics, Inc. (GYRE)
8.455
+0.42
(+5.16%)
USD |
NASDAQ |
Dec 10, 16:00
8.455
0.00 (0.00%)
After-Hours: 18:01
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 814.50M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -25.14% |
| Valuation | |
| PE Ratio | 222.50 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 7.776 |
| Price to Book Value | 7.992 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0114 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.99% |
Profile
| Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA. |
| URL | http://www.gyretx.com |
| Investor Relations URL | https://ir.gyretx.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 16, 2026 (est.) |
| Last Earnings Release | Nov. 07, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jan. 13, 2023 |
Ratings
Profile
| Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA. |
| URL | http://www.gyretx.com |
| Investor Relations URL | https://ir.gyretx.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 16, 2026 (est.) |
| Last Earnings Release | Nov. 07, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jan. 13, 2023 |